Stanniocalcin-1, a novel anti-inflammatory protein

Stanniocalcin-1,一种新型抗炎蛋白

基本信息

  • 批准号:
    7899903
  • 负责人:
  • 金额:
    $ 36.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-08-01 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Macrophages are important mediators of inflammation. Our data show stanniocalcin-1 (STC1) decreases macrophage response to chemoattractants and migration across an endothelial monolayer. STC1 also diminishes superoxide generation in macrophages, by inducing uncoupling protein-2 (UCP2), and inhibits the NF-?B pathway. In cultured endothelial cells, STC1 inhibits cytokine-induced changes in permeability and tight junction protein expression. STC1 transgenic mice, which exhibit elevated serum levels and preferential expression of STC1 in macrophages and endothelium, display less inflammatory macrophages in the glomeruli during anti-glomerular basement membrane (GBM) disease, resulting in kidney protection. Overall hypothesis: STC1 suppresses inflammation through inhibition of macrophage recruitment and function, and cytokine-induced increase in endothelial permeability. In Specific Aim I, we will determine mechanisms of UCP2 upregulation by STC1 and the role of superoxide in STC1-mediated inhibition of NF-?B in macrophages. In Specific Aim II, we will determine the effect of STC1 on cytokine-induced changes in expression and assembly of tight junction proteins in cultured primary kidney endothelial cells. In Specific Aim III, in the context of anti-GBM disease, we will examine endothelial permeability of native kidney vessels, as well as kidney inflammation and function, after kidney endothelium-specific or macrophage-specific overexpression or deletion of STC1. PUBLIC HEALTH RELEVANCE: Our preliminary results show stanniocalcin-1 protein inhibits macrophages, stabilizes blood vessels and decreases kidney inflammation. We plan to study how stanniocalcin-1 inhibits macrophages and how it stabilizes blood vessels during inflammation. This is important because available conventional therapies for inflammation are frequently associated with significant side effects, and our proposed experiments could lead to identification of new medications to treat inflammation.
描述(申请人提供):巨噬细胞是炎症的重要介质。我们的数据显示STC1降低巨噬细胞对化学引诱剂的反应和跨内皮单层的迁移。STC1还通过诱导解偶联蛋白2 (UCP2)减少巨噬细胞中超氧化物的产生,并抑制NF-?B通路。在培养的内皮细胞中,STC1抑制细胞因子诱导的通透性和紧密连接蛋白表达的变化。STC1转基因小鼠在抗肾小球基底膜(anti-glomerular basal membrane, GBM)疾病期间,肾小球内炎症性巨噬细胞减少,从而起到保护肾脏的作用,其血清水平升高,STC1在巨噬细胞和内皮中优先表达。总体假设:STC1通过抑制巨噬细胞募集和功能,以及细胞因子诱导的内皮通透性增加来抑制炎症。在Specific Aim I中,我们将确定STC1上调UCP2的机制以及超氧化物在STC1介导的NF-抑制中的作用。巨噬细胞中的B。在Specific Aim II中,我们将确定STC1对细胞因子诱导的培养的原代肾内皮细胞中紧密连接蛋白表达和组装变化的影响。在特异性目的III中,在抗gbm疾病的背景下,我们将检查肾脏内皮特异性或巨噬细胞特异性STC1过表达或缺失后天然肾脏血管的内皮通透性,以及肾脏炎症和功能。公共卫生相关性:我们的初步结果显示,斯坦钙素-1蛋白抑制巨噬细胞,稳定血管,减少肾脏炎症。我们计划研究斯坦钙素-1如何抑制巨噬细胞,以及它如何在炎症期间稳定血管。这一点很重要,因为现有的炎症常规疗法经常伴有明显的副作用,而我们提出的实验可能会导致发现治疗炎症的新药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID SHEIKH-HAMAD其他文献

DAVID SHEIKH-HAMAD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID SHEIKH-HAMAD', 18)}}的其他基金

Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    8824828
  • 财政年份:
    2014
  • 资助金额:
    $ 36.47万
  • 项目类别:
Megalin, mitochondrial intracrine signaling and the kidney
巨蛋白、线粒体内分泌信号传导和肾脏
  • 批准号:
    10427148
  • 财政年份:
    2014
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    8633244
  • 财政年份:
    2014
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1: New paradigms for cytoprotection and anti-inflammation
Stanniocalcin-1:细胞保护和抗炎的新范例
  • 批准号:
    9339510
  • 财政年份:
    2014
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8515390
  • 财政年份:
    2009
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8131592
  • 财政年份:
    2009
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    8320393
  • 财政年份:
    2009
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7729602
  • 财政年份:
    2009
  • 资助金额:
    $ 36.47万
  • 项目类别:
Stanniocalcin-1, a novel anti-inflammatory protein
Stanniocalcin-1,一种新型抗炎蛋白
  • 批准号:
    7687670
  • 财政年份:
    2009
  • 资助金额:
    $ 36.47万
  • 项目类别:
NIH INTRAMURAL NRSA INSTITUTIONAL TRAINING PROGRAM
NIH 校内 NRSA 机构培训计划
  • 批准号:
    2213315
  • 财政年份:
    1993
  • 资助金额:
    $ 36.47万
  • 项目类别:

相似海外基金

I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
    Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
    Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
    Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 36.47万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了